These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 36066961)
1. Microdosing psilocybin for chronic pain: a case series. Lyes M; Yang KH; Castellanos J; Furnish T Pain; 2023 Apr; 164(4):698-702. PubMed ID: 36066961 [TBL] [Abstract][Full Text] [Related]
2. Compassionate use of psychedelics. Greif A; Šurkala M Med Health Care Philos; 2020 Sep; 23(3):485-496. PubMed ID: 32468195 [TBL] [Abstract][Full Text] [Related]
3. Are psychedelics the answer to chronic pain: A review of current literature. Kooijman NI; Willegers T; Reuser A; Mulleners WM; Kramers C; Vissers KCP; van der Wal SEI Pain Pract; 2023 Apr; 23(4):447-458. PubMed ID: 36597700 [TBL] [Abstract][Full Text] [Related]
4. Beating pain with psychedelics: Matter over mind? Elman I; Pustilnik A; Borsook D Neurosci Biobehav Rev; 2022 Mar; 134():104482. PubMed ID: 34922987 [TBL] [Abstract][Full Text] [Related]
5. Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia. Glynos NG; Pierce J; Davis AK; McAfee J; Boehnke KF J Psychoactive Drugs; 2023; 55(1):73-84. PubMed ID: 35001856 [TBL] [Abstract][Full Text] [Related]
6. Psychedelics as preventive treatment in headache and chronic pain disorders. Schindler EAD Neuropharmacology; 2022 Sep; 215():109166. PubMed ID: 35718005 [TBL] [Abstract][Full Text] [Related]
7. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Carhart-Harris RL; Bolstridge M; Rucker J; Day CM; Erritzoe D; Kaelen M; Bloomfield M; Rickard JA; Forbes B; Feilding A; Taylor D; Pilling S; Curran VH; Nutt DJ Lancet Psychiatry; 2016 Jul; 3(7):619-27. PubMed ID: 27210031 [TBL] [Abstract][Full Text] [Related]
8. Psychedelic microdosing benefits and challenges: an empirical codebook. Anderson T; Petranker R; Christopher A; Rosenbaum D; Weissman C; Dinh-Williams LA; Hui K; Hapke E Harm Reduct J; 2019 Jul; 16(1):43. PubMed ID: 31288862 [TBL] [Abstract][Full Text] [Related]
9. Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology. Kelly DF; Heinzerling K; Sharma A; Gowrinathan S; Sergi K; Mallari RJ Neurosurgery; 2023 Apr; 92(4):680-694. PubMed ID: 36512813 [TBL] [Abstract][Full Text] [Related]
10. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. Smigielski L; Kometer M; Scheidegger M; Krähenmann R; Huber T; Vollenweider FX Sci Rep; 2019 Oct; 9(1):14914. PubMed ID: 31649304 [TBL] [Abstract][Full Text] [Related]
11. Microdosing psychedelics: Motivations, subjective effects and harm reduction. Lea T; Amada N; Jungaberle H; Schecke H; Klein M Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967 [TBL] [Abstract][Full Text] [Related]
12. Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms. Skosnik PD; Sloshower J; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC J Psychopharmacol; 2023 Jul; 37(7):687-697. PubMed ID: 37392016 [TBL] [Abstract][Full Text] [Related]
13. Dosing Psychedelics and MDMA. Liechti ME; Holze F Curr Top Behav Neurosci; 2022; 56():3-21. PubMed ID: 34734392 [TBL] [Abstract][Full Text] [Related]